FI7569U1 - Farmaseuttinen koostumus luun uudelleenmuovauksen häiriön hoitamiseksi tai estämiseksi - Google Patents

Farmaseuttinen koostumus luun uudelleenmuovauksen häiriön hoitamiseksi tai estämiseksi

Info

Publication number
FI7569U1
FI7569U1 FI20060389U FIU20060389U FI7569U1 FI 7569 U1 FI7569 U1 FI 7569U1 FI 20060389 U FI20060389 U FI 20060389U FI U20060389 U FIU20060389 U FI U20060389U FI 7569 U1 FI7569 U1 FI 7569U1
Authority
FI
Finland
Prior art keywords
disorder
treat
prevent
pharmaceutical composition
bone formation
Prior art date
Application number
FI20060389U
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Inventor
Nigel Atherton
Joseph W Totten
Michael Gaitonde
Original Assignee
Shire Int Licensing Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Int Licensing Bv filed Critical Shire Int Licensing Bv
Publication of FIU20060389U0 publication Critical patent/FIU20060389U0/fi
Application granted granted Critical
Publication of FI7569U1 publication Critical patent/FI7569U1/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/06—Chelate

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI20060389U 2000-06-27 2006-09-22 Farmaseuttinen koostumus luun uudelleenmuovauksen häiriön hoitamiseksi tai estämiseksi FI7569U1 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015745.3A GB0015745D0 (en) 2000-06-27 2000-06-27 Treatment of bone diseases
PCT/GB2001/002836 WO2002000227A2 (fr) 2000-06-27 2001-06-26 Traitement des maladies osseuses

Publications (2)

Publication Number Publication Date
FIU20060389U0 FIU20060389U0 (fi) 2006-09-22
FI7569U1 true FI7569U1 (fi) 2007-07-17

Family

ID=9894512

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20060389U FI7569U1 (fi) 2000-06-27 2006-09-22 Farmaseuttinen koostumus luun uudelleenmuovauksen häiriön hoitamiseksi tai estämiseksi

Country Status (11)

Country Link
US (2) US7078059B2 (fr)
EP (2) EP2052725A2 (fr)
JP (1) JP2004501198A (fr)
AT (2) ATE424837T1 (fr)
AU (2) AU2001274341B2 (fr)
CA (1) CA2415228C (fr)
DE (1) DE60137929D1 (fr)
DK (1) DK200600250U4 (fr)
FI (1) FI7569U1 (fr)
GB (1) GB0015745D0 (fr)
WO (1) WO2002000227A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100015246A1 (en) * 2000-06-27 2010-01-21 Shire International Licensing B.V. Combination of a lanthanum compound and bone enhancing agent for the treatment of bone diseases
US7858602B2 (en) * 2000-10-16 2010-12-28 Rodriguez Victorio C Therapeutic and prophylactic uses of cell specific carbonic anhydrase enzymes in treating aging disorders due to oxidative stress and as growth factors of stem cells
AU2003229437A1 (en) * 2002-05-08 2003-11-11 Shire Holding Ag Use of lanthanum for the treatment of hypercalcemia and bone metastasis
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
EP1647524A3 (fr) * 2002-08-14 2006-09-13 Altair Nanomaterials Inc. Composés de métaux de terres rares, procédés de production et d'utilisation de ces derniers
US7220406B2 (en) * 2002-10-22 2007-05-22 Genzyme Corporation Method for promoting bone formation
ES2394782T3 (es) * 2003-05-07 2013-02-05 Osteologix A/S Composición con estroncio y vitamina D para la profilaxis y/o tratamiento de afecciones de cartílagos y/o huesos
EP1745791B1 (fr) * 2003-05-07 2013-06-26 Osteologix A/S Sels de strontium hydrosolubles pour le traitement d'affections de cartilage et/ou d'os
EP1622629B1 (fr) * 2003-05-07 2013-07-10 Osteologix A/S Composition a libération controlée contenant un sel de strontium
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.
US7381428B2 (en) 2003-08-26 2008-06-03 Shire International Licensing B.V. Stabilized lanthanum carbonate compositions
JP4869229B2 (ja) * 2004-07-27 2012-02-08 シア ファーマシューティカルズ，インク． 水酸化炭酸ランタンを用いた高リン血症を治療するための医薬組成物
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
EP1698233A1 (fr) * 2005-03-01 2006-09-06 Bayer HealthCare AG Réduction de la digestibilité de phosphore dans la nutrition animale
US20080058250A1 (en) * 2005-08-17 2008-03-06 Allison Wren Treatment of chronic renal failure and other conditions in domestic animals: compositions and methods
WO2007130113A2 (fr) * 2005-09-06 2007-11-15 Zelos Therapeutics, Inc. Analogues de l'hormone parathyroidienne et procedes les utilisant
US20110046059A1 (en) * 2005-09-06 2011-02-24 Zelos Therapeutics, Inc. Pharmaceutically acceptable formulations/compositions for peptidyl drugs
US20070104799A1 (en) * 2005-11-09 2007-05-10 Shire International Licensing B.V. Treatment of chronic kidney disease (CKD) subjects using lanthanum compounds
US20070259052A1 (en) 2006-05-05 2007-11-08 Shire International Licensing B.V. Assay for lanthanum hydroxycarbonate
US20100285032A1 (en) * 2007-06-07 2010-11-11 Aubin Jane E Estrogen receptor-related receptor gamma (err gamma) in bone and cartilage formation and methods and compositions relating to same
GB0806801D0 (en) * 2008-04-15 2008-05-14 Immunodiagnostic Systems Ltd Substrate
US8961917B2 (en) 2010-05-12 2015-02-24 Spectrum Pharmaceuticals, Inc. Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
WO2011156583A1 (fr) 2010-06-10 2011-12-15 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Biomarqueurs isotopiques pour l'estimation rapide d'un équilibre minéral osseux dans des applications biomédicales
KR20180079450A (ko) * 2010-06-11 2018-07-10 몰리코프 미네랄스, 엘엘씨 폐수로부터 생리 활성 화합물의 개선
WO2015038582A2 (fr) * 2013-09-11 2015-03-19 New York University Procédés et compositions pour le traitement de maladies osseuses
EP3113859A4 (fr) 2014-03-07 2017-10-04 Secure Natural Resources LLC Oxyde de cérium (iv) ayant d'exceptionnelles propriétés d'élimination de l'arsenic
EP2932974A1 (fr) * 2014-04-15 2015-10-21 Chemische Fabrik Budenheim KG Composition pour la prophylaxie et le traitement de troubles osseux
WO2025152053A1 (fr) * 2024-01-17 2025-07-24 内蒙古医科大学 Utilisation de lanthane soluble dans l'amélioration de l'arthrite

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2493704A1 (fr) 1980-11-07 1982-05-14 Lemouel Jean Composition pour la prophylaxie et les soins de la carie dentaire
US5869473A (en) * 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5171583A (en) 1988-10-21 1992-12-15 The Regents Of The University Of California Treatment of osteoporosis using potassium bicarbonate
US5342604A (en) * 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5696239A (en) * 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
GB9506126D0 (en) 1995-03-25 1995-05-10 Johnson Matthey Plc Pharmaceutical composition and method
US5902825A (en) * 1997-01-07 1999-05-11 Mitreoak, Ltd. Composition and method for the palliation of pain associated with diseases of the bone and bone joints
DE60120458T2 (de) * 2000-10-13 2007-01-11 Abbott Laboratories, Abbott Park Verfahren zur bestimmung der anfangsdosis von vitamin d verbindungen
WO2004030669A1 (fr) * 2002-09-30 2004-04-15 Schering Corporation Utilisation d'amides tricycliques en vue de traiter des troubles lies a l'homeostasie calcique
MXPA06002257A (es) * 2003-08-26 2006-05-17 Shire Holdings Ag Farmaceutica que comprende compuestos de lantano.

Also Published As

Publication number Publication date
DK200600250U4 (da) 2008-09-12
GB0015745D0 (en) 2000-08-16
EP2052725A2 (fr) 2009-04-29
WO2002000227A3 (fr) 2002-08-29
WO2002000227A2 (fr) 2002-01-03
DK200600250U1 (da) 2007-01-12
AT9687U1 (de) 2008-02-15
US7078059B2 (en) 2006-07-18
ATE424837T1 (de) 2009-03-15
CA2415228C (fr) 2011-09-06
EP1294384A2 (fr) 2003-03-26
AU2001274341B2 (en) 2006-10-19
US20020051822A1 (en) 2002-05-02
EP1294384B1 (fr) 2009-03-11
JP2004501198A (ja) 2004-01-15
US20070048390A1 (en) 2007-03-01
DE60137929D1 (de) 2009-04-23
CA2415228A1 (fr) 2002-01-03
FIU20060389U0 (fi) 2006-09-22
WO2002000227A8 (fr) 2004-04-15
AU7434101A (en) 2002-01-08

Similar Documents

Publication Publication Date Title
FI7569U1 (fi) Farmaseuttinen koostumus luun uudelleenmuovauksen häiriön hoitamiseksi tai estämiseksi
EE200000484A (et) Täiustused ravimi väljastusseadmetele
ATE392890T1 (de) Hydrogel-gesteuerte dosierungsform
NO20035645L (no) Forsterket medikamentlevering i transdermale systemer
DE60010456D1 (de) Pharmazeutische oder diätetische zusammensetzung zur prävention oder behandlung von hyperoxalurie
DE69923076D1 (de) Transthorakale arzneimittelabgabevorrichtung
NO20015175L (no) Farmasöytisk sammensetning
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
NO2013004I2 (no) Axitinib, valgfritt i form av et farmasøytisk aksentabelt salt
FI991485L (fi) Uusi farmaseuttinen koostumus
ATE355271T1 (de) Pharmazeutische zusammensetzung
DE60015279D1 (de) Stabilisierte pharmazeutische zusammentsetzung in lyophilisierter form
NO331218B1 (no) Transdermalt befruktningshindrende avleveringssystem
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
ATE366128T1 (de) Pharmazeutische zusammensetzung
FI4488U1 (fi) Farmaseuttinen koostumus
GB0018342D0 (en) Improvements in or relating to inhaler devices
DE60142515D1 (de) Zusammensetzungen zur vorbeugung von geschwüren in pferden
ID29969A (id) Peralatan untuk mendistribusikan adonan dalam pengekstrusi
ATE299704T1 (de) Warmgeformte feste arzneizusammensetzung zur gesteuerten wirkstoffabgabe von perindopril
AU8679801A (en) Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions
EE200200229A (et) Diarüülenüünid, kompositsioon ja farmatseutiline kompositsioon
GB0002454D0 (en) Improvements in or relating to organic compostions
DK1107777T3 (da) Stabiliseret farmaceutisk præparat i lyofiliseret form
EP1195164A4 (fr) Remedes contre l'hypercalcemie chimio-resistante

Legal Events

Date Code Title Description
FGU Utility model registered

Ref document number: 7569

Country of ref document: FI

MAU Utility model expired